UNASSIGNED: @entity4585 ( @entity4585 ) is defined as a @entity5 mass consisting of myeloid blast with or without maturation occurring at an anatomical site other than bone marrow with normal architectural effacement. It can also precede the onset of @entity1778 which is called @entity2800 . @entity2800 is a kind of @entity395 and easy to be misdiagnosed as other common @entity5 due to the rarity and nonspecific manifestation. We herein report an unusual case of @entity2800 , and cervix in a female @entity1 . The bone marrow aspiration and biopsy of the @entity1 revealed no @entity1503 . Immunohistochemical staining of the biopsies was strongly positive for @entity3335 , @entity469 , leukocyte common antigen (LCA), @entity2467 , @entity2280 , @entity3053 , @entity7571 , and negative for cytokeratin (CK), epithelial memberane antigen (EMA), @entity3138 , CD3, @entity2225 , @entity5893 , @entity13221 . Then a diagnosis of @entity2800 was made. Unfortunately, our @entity1 received only one cycle of chemotherapy consisting of @entity2592 and @entity5699 , then refused any further treatment and died 4 months after diagnosis. Although systemic chemotherapy is widely accepted to be a promising strategy, its benefit still needs to be further assessed. Certain questions still need to be answered for this disease: 1) Why can approximately 20% of the @entity1 with @entity2800 remain disease-free after local therapy alone? 2) How many cycles of chemotherapy are needed for these @entity1 after achievement of complete remission? 3) What are the prognostic or risk factors in these @entity1 who have no abnormality of karyotype, fusion genes, or gene mutation to predict responsiveness to chemotherapy and outcome? 4) What is the risk factor for relapse? The rarity of @entity2800 makes it almost impossible to conduct large-scale randomized trials, but judicious study for each @entity1 with @entity4585 is helpful for a further understanding of the nature of the disease.

XXXX involving the vulva, vagina, and cervix: a case report and literature review.

@entity1 :: ('9606', 'Species') :: ['patient', 'patients'] @entity7571 :: ('973', 'Gene') :: ['CD79a'] @entity3335 :: ('4353', 'Gene') :: ['myeloperoxidase'] @entity5699 :: ('MESH:D003630', 'Chemical') :: ['daunorubicin'] @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancies', 'tumor'] @entity469 :: ('968', 'Gene') :: ['CD68'] @entity2225 :: ('54474', 'Gene') :: ['CD20'] @entity2800 :: ('MESH:D007951', 'Disease') :: ['non-leukemic MS involving the vulva, vagina', 'non-leukemic MS', 'Non-leukemic MS'] @entity3138 :: ('914', 'Gene') :: ['CD2'] @entity5893 :: ('921', 'Gene') :: ['CD5'] @entity1503 :: ('MESH:D006402', 'Disease') :: ['hematological abnormality'] @entity13221 :: ('6382', 'Gene') :: ['CD138'] @entity1778 :: ('MESH:D007938', 'Disease') :: ['leukemia'] @entity2592 :: ('MESH:D003561', 'Chemical') :: ['cytosine arabinoside'] @entity3053 :: ('952', 'Gene') :: ['CD38'] @entity2467 :: ('3815', 'Gene') :: ['CD117'] @entity395 :: ('MESH:D035583', 'Disease') :: ['rare disease'] @entity2280 :: ('947', 'Gene') :: ['CD34'] @entity4585 :: ('MESH:D023981', 'Disease') :: ['MS', 'Myeloid sarcoma']
@entity2800 :: (MESH:D007951,Disease) :: ['Non-leukemic myeloid sarcoma']
